Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03

被引：0

作者：

Yasuaki Sagara

Masahiro Takada

Yasuyo Ohi

Shoichiro Ohtani

Sasagu Kurozumi

Kenichi Inoue

Yoshimasa Kosaka

Masaya Hattori

Toshinari Yamashita

Shintaro Takao

Nobuaki Sato

Hiroji Iwata

Masafumi Kurosumi

Masakazu Toi

机构：

[1] Kyoto University Graduate School of Medicine,Department of Breast Surgery

[2] Social Medical Cooperation Hakuaikai,Department of Breast Surgical Oncology

[3] Social Medical Cooperation Hakuaikai,Department of Pathology

[4] Hiroshima City Hospital,Department of Breast Surgery

[5] Gunma University Graduate School of Medicine,Department of General Surgical Science

[6] Saitama Cancer Center,Department of Breast Oncology

[7] Kitasato University School of Medicine,Department of Breast and Endocrine Surgery

[8] Aichi Cancer Center Hospital,Department of Breast Oncology

[9] Kanagawa Cancer Center,Department of Breast and Endocrine Surgery

[10] Hyogo Cancer Center,Department of Breast Surgery

[11] Niigata Cancer Center Hospital,Department of Breast Surgery

[12] Saitama Cancer Center,Department of Pathology

来源：

Breast Cancer Research and Treatment | 2018年 / 171卷

关键词：

HER2; Basal marker; Basal HER2; Trastuzumab; Neo-adjuvant;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：675 / 683

页数：8

共 111 条

[1] Zardavas D(2015)Clinical management of breast cancer heterogeneity Nat Rev Clin Oncol 12 381-394
[2] Irrthum A(2014)Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer J Natl Cancer Inst 106 1-8
[3] Swanton C(2015)In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer Nat Genet 47 1212-1219
[4] Prat A(2012)Trastuzumab containing regimens for early breast cancer Cochrane Database Syst Rev 377 122-131
[5] Carey LA(2017)Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer N Engl J Med 295 2492-2502
[6] Adamo B(2006)Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study JAMA 378 1812-1823
[7] Janiszewska M(2011)Gene expression profiling in breast cancer: classification, prognostication, and prediction Lancet 98 10869-10874
[8] Liu L(2001)Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 406 747-752
[9] Almendro V(2000)Molecular portraits of human breast tumours Nature 19 935-940
[10] Moja L(2012)Prognostic value of basal phenotype in HER2-overexpressing breast cancer Ann Surg Oncol 39 167-174